Stanford

Mengxiong Wang

Basic Life Research Scientist, Radiation Oncology - Radiation Biology

Publications

PUBLICATIONS

- **Analysis of knockout mice reveals critical female-specific roles for the Hippo pathway component PTPN14.** *Genes & development*
  McCrea, E. M., Makrides, N., Tabata, T., Reineking, W., Vilches-Moure, J. G., Wang, M., Lake, J. S., Vogel, H., Howitt, B., Zhang, X., Attardi, L. D.
  2025

- **Integrative multiomic approaches reveal ZMAT3 and p21 as conserved hubs in the p53 tumor suppression network.** *Cell death and differentiation*
  Boutelle, A. M., Mabene, A. R., Yao, D., Xu, H., Wang, M., Tang, Y. J., Lopez, S. S., Sinha, S., Demeter, J., Cheng, R., Benard, B. A., McCrea, E. M., Valente, et al
  2025

- **Activating p53Y220C with a Mutant-Specific Small Molecule.** *bioRxiv : the preprint server for biology*
  Zhu, X., Byun, W. S., Pieńkowska, D. E., Nguyen, K. T., Gerhartz, J., Geng, Q., Qiu, T., Zhong, J., Jiang, Z., Wang, M., Sarott, R. C., Hinshaw, S. M., Zhang, et al
  2024

- **DR5 disulfide bonding functions as a sensor and effector of protein folding stress.** *Molecular cancer research : MCR*
  Law, M. E., Dulloo, Z. M., Eggleston, S. R., Takacs, G. P., Alexandrow, G. M., Lee, Y. I., Wang, M., Hardy, B., Su, H., Forsyth, B., Das, P., Datta, P. K., Chiang, et al
  2024

- **p53 governs an AT1 differentiation programme in lung cancer suppression.** *Nature*
  Kaiser, A. M., Gatto, A., Hanson, K. J., Zhao, R. L., Raj, N., Ozawa, M. G., Seoane, J. A., Bieging-Rolett, K. T., Wang, M., Li, I., Trope, W. L., Liou, D. Z., Shrager, et al
  2023

- **The Mettl3 epitranscriptomic writer amplifies p53 stress responses.** *Molecular cell*
  Raj, N., Wang, M., Seoane, J. A., Zhao, R. L., Kaiser, A. M., Moonie, N. A., Demeter, J., Boutelle, A. M., Kerr, C. H., Mulligan, A. S., Moffatt, C., Zeng, S. X., Lu, et al
  2022

- **A Balancing Act: p53 Activity from Tumor Suppression to Pathology and Therapeutic Implications.** *Annual review of pathology*
  Wang, M., Attardi, L. D.
  2021

- **Zmat3 Is a Key Splicing Regulator in the p53 Tumor Suppression Program.** *Molecular cell*
  Bieging-Rolett, K. T., Kaiser, A. M., Morgens, D. W., Boutelle, A. M., Seoane, J. A., Van Nostrand, E. L., Zhu, C., Houlihan, S. L., Mello, S. S., Yee, B. A., McClendon, J., Pierce, S. E., Winters, et al
  2020; 80 (3): 452

- **A novel proteotoxic combination therapy for EGFR+ and HER2+cancers** *ONCOGENE*
  Wang, M., Ferreira, R. B., Law, M. E., Davis, B. J., Yaaghubi, E., Ghilardi, A. F., Sharma, A., Avery, B. A., Rodriguez, E., Chiang, C., Narayan, S., Heldermon, C. D., Castellano, et al
  2019; 38 (22): 4264–82

- **The unfolded protein response as a target for anticancer therapeutics** *CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY*
  Wang, M., Law, M. E., Castellano, R. K., Law, B. K.

2018; 127: 66–79

- **Disulfide bond disrupting agents activate the unfolded protein response in EGFR- and HER2-positive breast tumor cells** *ONCOTARGET*
  Ferreira, R. B., Wang, M., Law, M. E., Davis, B. J., Bartley, A. N., Higgins, P. J., Kilberg, M. S., Santostefano, K. E., Terada, N., Heldermon, C. D., Castellano, R. K., Law, B. K.
  2017; 8 (17): 28971–89